gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin qure hemb data recap preview
highlight week februari februari uniqur buy chardan top pick announc
updat data phase iib dose-confirm studi gene therapi gt
hemophilia mean activ across patient normal week post-
treatment data continu suggest could produc activ level rang phase
studi would make patient phenotyp normal possibl make function cure uniqur also
announc dose patient pivot phase hope-b trial mean
compani track readout like market leadership hemophilia gt thereaft solid bioscienc
buy report preliminari find phase i/ii ignit dmd trial duchenn muscular
dystrophi dmd patient treat vg/kg aav-bas gt show low level microdystrophin
express normal solid current take step proceed dose-escal plan provid
data ignit dmd later despit setback assum better safe data dose-escal
see opportun solid viabl player dmd space competitor unabl suppli entir
market understand case unrat announc interim data
on-going vivo zfn gene edit trial phase i/ii empow studi mp
phase i/ii champion studi mp ii studi provid limit evid efficaci
chang plasma iuda enzym level urinari gag treatment small chang id enzym
level still normal rang chang urinari gag treatment gensight biolog
neutral announc phase rescu trial aav-bas gt lhon meet
primari endpoint phase revers trial read april rescu
demonstr differ visual acuiti treat untreat eye statist
differ secondari endpoint data downgrad sight buy neutral chardan publish
viral news genet medicin review expect show bold predict
happen chardan genet medicin alpha portfolio gmap continu gener high alpha
look forward februari februari februari ceo investor confer take
place new york ny numer compani across genet medicin space particip includ alnylam
buy chardan top pick arcturu therapeut buy oncosec unrat senti bioscienc privat
sirnaom privat februari et uniqur buy leonard director global
patient advocaci particip panel discuss part massbio forum gene therapi
tale persever incept today cambridg
weekli price move figur vivo genet medicin aav srna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
march chardan sponsor gene therapi genom edit summit host orphan
march chardan sponsor arm cell gene therapi investor day new york citi
pleas refer import disclosur inform regul analyst certif found page report
april chardan sponsor arm meet mediterranean barcelona
viral news genet medicin review expect februari amusa
sight downgrad neutral rescu former buy thesi februari amusa
gensight biolog announc phase rescu trial aav-bas gt
leber hereditari optic neuropathi lhon meet primari endpoint differ visual
acuiti improv eye compar sham-treat eye week
sham-treat eye perform similarli vision declin nadir rebound slightli
week eye chang etdr letter sham-treat eye chang
letter recal phase revers trial also fail meet primari endpoint
news reduc price target feel prior probabl success
describ april research optimist valu gensight premium
cash thu downgrad compani rate buy neutral
qure buy hope-b track readout dose start februari amusa
uniqur chardan top pick announc dose patient pivot phase hope-b trial
gt hemophilia uniqur intend complet enrol
us news evid uniqur track report data hope-b also see like
uniqur well ahead unrat conduct phase registri
commenc treatment unabl trial protocol result on-going phase
trial gt hemophilia biomarin unrat may read-across uniqur base
similar vector manufactur process
equiti offer biomarin back phase data could facilit increas interest uniqur
neutral at-gaa datamor gt arriv februari amusa
amicu announc data updat phase i/ii trial ert/chaperon
combin at-gaa pomp diseas show stabil efficaci highli align
data expect posit amicu note clinic gt competit pomp diseas exist
cbio buy synthet transgen activ -padua februari amusa
catalyst bioscienc announc aav-bas gt candid cb mous model hemophilia
show reduct bleed time improv clot activ compar gt use fix-
padua construct week treatment
given fix-padua patent held uniqur catalyst construct use hyperact protein may valuabl
megacap hemophilia player look gt exposur hemophilia space
buy dose escal plan low level microdystrophin februari amusa
solid bioscienc report preliminari find patient phase i/ii ignit dmd trial
aav-bas gt show low level microdystrophin express vg/
kg dose solid plan dose-escal explain potenti better result higher dose level
view differ dose solid sarepta unrat on-going trial vg/kg solid versu
vg/kg sarepta fulli explain differ result compani achiev unless
threshold effect requir minimum dose robust protein express note howev sarepta may
encount issu relat scalabl cost per patient may constrain abil suppli market
knowledg unabl fulli suppli dmd market may still
possibl solid viabl player assum effect dose-escal without safeti recruit issu
news unknown dose-escal reduc po drove
price target reduct buy rate unchang
qure buy say piib data point qure target februari amusa
page
uniqur chardan top pick announc week data patient phase iib dose-confirm
studi gt hemophilia new result show mean activ
normal week sustain activ level week result alreadi
estim rang week post treatment per uniqur octob corpor present
result import sinc patient dose low-level pre-exist neutral antibodi
obtain high activ without immunosuppress uniqur like broad scope success treat
patient given treat patient resolv hepat hiv-posit
phase iib data continu support blockbust opportun make hemophilia patient
phenotyp normal expect robust efficaci continu updat phase iib data consist
prior estim activ level associ treatment phase iib and/or phase studi
could year year post-treat beyond
updat clinic program februari naka
arrowhead buy report fiscal result ep reflect mm
defer revenu johnson johnson compani unrat collabor
licens agreement aro-hbv compani subcutan administ rnai therapeut hbv
compani also began dose phase studi dyslipidemia file
cta hypertriglyceridemia data program expect
maintain buy rate price target believ licens deal janssen
reduc risk stock hbv program initi data aro-hbv aro-aat program provid
read-across compani liver diseas program target hepatocyt cell util trim platform
buy report result report revenu mm consist
mm product sale onpattro compani commercially-avail rnai therapeut treatment
hereditari attr amyloidosi mm collabor
compani provid updat guidanc clinic pipelin top-line data phase envis trial
givosiran treat acut hepat porphyria ahp slate march full data present
intern liver congress european associ studi liver easl april
alnylam plan begin roll submiss nda march potenti full submiss
could support approv
maintain buy rate price target believ alnylam clear leader rnai space
competit scale experi patent breadth pipelin access capit compani rnai platform
valid approv last year onpattro parti collabor big pharma
advanc addit asset current evalu phase studi
genet medicin news februari februari
qure buy announc treatment patient piii hope-b trial hem februari
curevac privat appoint dr stefan mueller vice-president preclin februari
edigen privat rais mm seri pre-b plu financ februari
unrat appoint dr shehnaaz suliman board director februari
sight-fp neutral announc top-line result piii rescu trial lhon februari
unrat announc full year financi result februari
unrat announc increas quarterli dividend begin februari
cavogen lifesci privat appoint scott fisher ceo februari
uc berkeley publish natur new famili genome-edit enzym crisprcasx februari
unrat announc patient dose phase trial februari
monoclon antibodi chikungunya viru encod mrna
administ lipid nanoparticl lnp formul intraven infus
mark time human dose monoclon antibodi encod mrna candid
system therapeut franchis dose human phase studi evalu
safeti toler escal dose healthi adult
ind open anoth candid modal methylmalon acidemia mma
page
decibel tx privat appoint peter weber promot paula cobb februari
unrat announc fda clearanc ind r/r hematolog malign februari
off-the-shelf natur killer nk cell product deriv genet engin
induc pluripot stem cell ipsc express fc receptor compani plan test
monotherapi acut myelogen leukemia aml combin rituximab non-hodgkin lymphoma nhl
combin elotuzumab multipl myeloma mm
cell-bas therapeut deriv genet engin ipsc clear clinic test
ind non-genet engin ipsc-deriv nk cell candid treatment advanc solid
tumor combin checkpoint blockad clear fda novemb
buy appoint eric ek interim cfo david scadden board director februari
unrat announc data updat pi ii studi fabri diseas februari
buy publish result pi studi givosiran acut intermitt porphyria nejm februari
eukar privat publish artifici express system februari
oxb unrat announc sanofi seek new partner oxb outlicens ophthalmolog februari
buy announc preliminari pi/ii data dmd intent dose escal februari
unrat appoint mythili koneru senior vice-president clinic develop februari
helixnano privat receiv grant develop machin learn person cancer vaccin februari
agtc neutral announc financi result busi updat quarter end dec februari
unrat announc interim phase i/ii champion studi data mp ii februari
sangamo present data patient phase i/ii trial
base zfn vivo genom edit product treatment mp ii also known hunter syndrom
worldsymposium test dose cohort vg/kg vg/kg vg/kg
liver biopsi patient mid-dos cohort show sign vivo edit measur express
chimer albumin-id transcript would occur upon transgen integr gene locu howev
transcript could detect rt-qpcr miseq lower limit detect
suggest actual edit rate level transcript could detect patient low-
dose cohort biopsi data avail biopsi data high-dos patient anticip later year
patient biochem data avail patient receiv mid-dos patient receiv
high-dos small increas id enzym activ compar baselin week measur
remain within expect rang baselin valu less nmol/hour/ml compar normal rang
estim greater nmol/hour/ml
safeti gener well toler total drug-rel across patient resolv
treatment-rel seriou advers event howev patient high-dos cohort develop transamin
understand compani believ could due immun respons
sangamo state econd-gener zfn incorpor technolog improv potenti increas efficaci
expect avail evalu clinic later year gen zfn shown higher
edit effici preclin studi
unrat announc interim phase i/ii empow studi data mp februari
sangamo present data patient phase i/ii trial
base zinc finger nucleas zfn vivo genom edit product mp also known hurler syndrom
worldsymposium test dose cohort vg/kg vg/kg
increas leukocyt idua activ observ subject rise baselin normal rang
nmol/hr/mg measur nmol/hr/mg last report assess compani report
signific chang plasma idua activ level glycosaminoglycan gag substrat biomark urin
await liver biopsi data taken week post-treat confirm edit activ
neurogen privat present preclin data aav-bas gt agu februari
buy announc full year financi result busi updat februari
buy announc financi result busi updat quarter end dec februari
page
axon neutral announc financi result busi updat quarter end dec februari
sight-fp neutral publish immun respons intravitr gt februari
qure buy announc data updat phase iib studi hemophilia februari
uspto issu notic allow uc berkeley foundat patent februari
brainvecti privat rais mm advanc aav gt neurodegen diseas februari
compani mention report
page
select catalyst genet medicin coverag
axo-lenti-pd report data first patient sunrise-pd phase i/ii trial
present data immun mechan action ovarian cancer
givosiran report top-line data envis piii trial acut hepat porphyria ahp
provid initi data phase trial tay-sachs/sandhoff diseas
submit ind chronic wound
initi phase i/ii trial autosom recess congenit ichthyosi
dcr-phxc initi phase ii/iii primari hyperoxaluria pend regulatori feedback
file ind rett syndrom
provid program updat phase i/ii valen trial crigler-najjar syndrom
provid continu regulatori updat x-link myotubular myopathi xlmtm
aro-aat initi phase ii/iii studi liver diseas
zolgensma provid clinic data readout strong phase studi sma type
zolgensma anticip regulatori decis sma type
present updat clinic data xlmtm
provid program overview undisclos larg neuromuscular diseas
vy-aadc provid longer term data phase ib trial pd
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
report result piii revers trial result piii rescu trial lhon
file ind inherit amyotroph later sclerosi
file ind cta pomp diseas
complet enrol dose escal phase i/ii trial achm
complet enrol phase iia studi wet
resum enrol phase i/ii studi hofh
dose patient phase trial gangliosidosi
provid earli data cohort phase i/ii pioneer trial n- rp
releas cgmp manufactur phase i/ii studi
initi phase i/ii trial
aav-rpgr prelim dose escal data phase i/ii trial xlrp
optogenet candid collab w/ bionic sight file ind advanc retin diseas
 fc report plan interim readout phase trial rhgg
initi trial malign
complet phase i/ii gem studi dystroph epidermolysi bullosa deb
complet ind-en studi diseas
dose patient phase studi mp
zolgensma anticip approv eu
lumasiran initi illuminate-b -c phase trial
givosiran complet nda applic file applic ahp
provid updat phase i/ii studi hemophilia
report phase i/ii data
provid prelim data phase i/ii patient defici
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
figur expect zolgensma approv price anticip broad implic vivo gt space
page
select catalyst genet medicin coverag
file ind pomp diseas
submit ema lhon
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm/xlrp
xlrp report interim data expans arm phase i/ii trial xlrp
file ind phase ii studi addit propos ophthalm indic
present interim data updat phase i/ii studi mp ii
present interim updat phase studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
initi phase trial dystroph epidermolysi bullosa deb
file ind ornithin transcarbamylas over-the-counter defici
provid initi data phase trial gangliosidosi
axo-aav-opmd initi clinic trial opmd phase specifi
report interim phase i/ii data rix nidcr/nih
initi dose phase trial hemophilia
dcr-hbv anticip first interim data clinic trial hbv
initi phase i/ii clinic trial huntington diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
updat dose escal pi/ii ignit trial dmd
cemdisiran initi phase ii studi iga nephropathi
initi phase i/ii trial
zolgensma complet strong phase trial pre-symptomat sma type
provid updat initi safeti studi hemophilia without inhibitor
 aro-enac file clear cell renal cell carcinoma cystic fibrosi
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
report preliminari data phase i/ii studi batten diseas
submit ind methylmalon acidemia mma
present preclin data new gt program fabri pomp defici
initi phase i/ii trial sjogren syndrom
file ind initi phase i/ii trial al
file ind initi phase i/ii trial wet
initi phase i/ii studi best diseas
 file ind al huntington diseas program
provid follow-up data piib dose-confirm studi hemb
present top-lin data phase i/iia clinic trial wet
initi pivot trial
 fc report final analysi phase trial rhgg
declar develop candid aml
figur alnylam/mdco meira gtx nightstar solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
figur plan file bla aadc defici
begin dose patient investigator-sponsor phase i/ii trial cystinosi
submit ind infantil batten diseas
report interim phase ii data recess dystroph epidermolysi bullosa
initi phase dose escal studi danon diseas
initi phase trial recess dystroph epidermolysi bullosa
 anticip data readout phase trial hd
initi phase ii trial multipl tumor type
begin patient dose phase trial
submit ind relapsed/refractori non-hodgkin lymphoma r/r nhl
aft spear cell report data phase trial hepatocellular carcinoma
initi clinic trial fanconi anemia use process product
submit ind gangliosidosi
initi pivot phase trial rdeb
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valoctocogen roxaparvovec valrox provid pi/ii data updat hem
valrox present full piii top-line data hem
valrox submit bla pend fda feedback hemophilia
bmn file ind phenylketonuria pku
provid dystrophin data phase trial dmd
provid interim dystrophin data preclin studi dma
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
ptc-fa file ind friedreich ataxia fa enter clinic
initi clinic trial charcot-marie-tooth type
lentiglobin initi phase studi sickl cell diseas
initi phase i/ii trial type gaucher diseas
file approv transit clinic trial platform manufactur
report data updat phase i/ii trial hemophilia
initi phase i/ii trial adult phenylketonuria
initi phase i/ii trial leukocyt adhes deficiency-i
rituximab report preliminari phase cohort expans data r/r nhl
sea-bcma report preliminari phase dose escal data r/r mm
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
micro-dystrophin initi confirmatori trial commerci materi dmd
tegsedi expect approv brazil hattr amyloidosi
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end februari vivo gm perform driven ivg
page
week-over-week perform vivo genet medicin aav small rna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm appli genet rna therapytickerratingccm ptupsideclosechang changemc mm arrowhead gene editingtickerratingccm ptupsideclosechang changemc mm pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note although avx acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur small rna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy nite buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular askbio estev horama myonexu stride tamid
small rna therapi comp alnylam top pick srna gene therapi offer favor risk-reward dynam
corpor report factset chardan note mention stock unrat unless state target market cap uncov name rgl silenc model current market cap
figur select public small rna therapi companiesw prefer buy greater potenti drive upsid entir small rna space
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat small rna therapi companiesadvirna silense sirnaom somagen sylentisnot adhera benitec biopharma addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan poseida precis scienc recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
price prv
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
